Navigation Links
Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock
Date:2/24/2009

MONTVALE, N.J., Feb. 24 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) today announced that it has entered into agreements with the current holders of its Series B Preferred Stock, $0.01 par value per share, under which $2,875,000 in accrued dividend obligations relating to the Series B Preferred Stock as of December 31, 2008 has been converted into senior secured promissory notes, due three years from the date of issuance. Interest at the rate of 1.25% per year shall be payable on the notes at maturity. The notes are secured by all of the Company's diagnostic assets, including the Company's HAPTOCHEK(TM) clinical diagnostic test for Hp2-2 diabetes, and its test to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

The holders of the Series B Preferred Stock have waived their rights to receive accruing dividends in cash during the term of the notes, provided there is no event of default under the notes and the notes remain outstanding. If the notes are repaid pursuant to the terms of the notes, and the Series B Preferred Stock remains outstanding at that time, the right of the Series B holders to receive any future dividends in cash shall resume. In addition, the right of the Series B holders to receive any accrued dividends in cash will resume upon the maturity of the notes.

The Company also announced that it has notified NYSE Alternext US LLC of its intent to voluntarily delist its common stock from trading on the NYSE Alternext. Following the delisting, the Company intends to voluntarily terminate the registration of its common stock under the Securities Exchange Act of 1934, as amended ("Exchange Act"), and thereafter to cease filing reports with the Securities and Exchange Commission ("SEC").

As previously announced on December 24, 2008, Synvista is currently not in compliance with certain NYSE Alternext continued listing standa
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
2. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
3. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
4. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
5. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
6. Synvista Therapeutics Posts Letter to Stockholders on Web Site
7. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
8. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
9. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
10. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
11. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... Albany, New York (PRWEB) July 12, 2014 ... market analysis for various reagents used in ... biotechnology is driving the life science reagents ... this study include manufacturers and providers of ... Science Reagents Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . ...
(Date:7/11/2014)... July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a website ... are used solely in scientific experiments, is currently celebrating ... in business, Maxim Peptide, which was created by the ... new and updated website that now features a special ... been updated with fascinating articles about peptide research, including ...
(Date:7/11/2014)... , July 11, 2014 , ... part) in, into or from any jurisdiction where to do ... such jurisdiction.  Shire plc ("Shire" or the "Company") ... article this afternoon.  Shire confirms it has held a meeting ... made by Shire without the prior agreement or approval of ...
(Date:7/11/2014)... Research and Markets  has announced the ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is ... or RNA) into cells. This technology helps the cells ... protein metabolism by affecting the nuclear genes. The transfection ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2
... - Neuro-Biotech Corporation (PINKSHEETS: MRES) (OTCQB: MRES) ... in the unique international niche of clinical ... opportunity to market 12 clinical "Neuro Blood ... are without equal in being rapidly done ...
... Inc. (Nasdaq: KERX ) today announced that Ron ... the 2010 UBS Global Life Sciences Conference, being held at ... presentation is scheduled to take place on Wednesday, September 22, ... of Mr. Bentsur,s presentation will be accessible from the Investor ...
... Epitomics, Inc. today announced that The Michael J. ... company to distribute a panel of LRRK2 monoclonal antibodies ... parties. Under a special arrangement the antibodies are being ... community to help advance LRRK2 therapeutic development efforts. The ...
Cached Biology Technology:Neuro-Biotech's Solution for a Doctor near You: Early Detection for Alzheimer's and Chronic Fatigue Syndrome! 2Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference 2Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation 2
(Date:7/11/2014)... report from the Wildlife Conservation Society shows that ... economically valuable species such as lobster, conch, and ... re-colonize nearby reef areas. , The reporttitled "Review ... review of research literature from no-take areas around ... Craig Dahlgren, a recognized expert in marine protected ...
(Date:7/11/2014)... 2014--Researchers at the Department of Energy,s Oak Ridge ... presented by R&D Magazine in recognition of the ... recognize the tremendous value of our National Labs," ... development at the National Labs continues to help ... the scientific and technological innovations necessary to remain ...
(Date:7/11/2014)... There were many fires burning in eastern New South ... July 11. , At 03:35 UTC on July 11 ... when Aqua passed over eastern New South Wales (NSW), ... natural-color visible image of the region and spotted smoke ... by MODIS,s thermal bands, are outlined in red. , ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... large urban areas are at a significantly higher risk ... giving birth compared to those living in rural areas, ... College Hospital,s Dr. Simone Vigod. The study, ... , strongly links geographic location and postpartum depression. The ...
... and colleagues from Chengde Medical College have shown ... heme oxygenase-1 expression in the hippocampus and cerebral ... in diabetic rats, thus protecting the nervous system. ... growth factor 1 axis undergoes abnormal changes in ...
... Energy Department,s National Renewable Energy Laboratory (NREL) has published ... power plants based on actual land-use practices from existing ... of the solar plants in the United States will ... author Sean Ong said. The report, "Land-use Requirements for ...
Cached Biology News:Women in urban areas show high rates of postpartum depression, study finds 2NREL report firms up land-use requirements of solar 2
CELLine System cultivation flask (for secreted products)...
... StabilCoat Plus Microsphere/Microarray Stabilizer is an aqueous ... and other non-toxic chemicals in a PBS ... 7.4. This product contains a combination ... a preservative. StabilCoat Plus Stabilizer provides ...
... The mini incubation trays are ... to screen antigens that have ... Each tray has eight 10.5 ... that accommodate strips cut from ...
... designed for quick and easy protein purification ... two 0.25mm holes laser cut at the ... remain liquid-tight during incubation of the gel ... protein diffuses from the gel into the ...
Biology Products: